Guido Jozef Tricot
Physician in Salt Lake City, UT
License number
Utah 6630705-8017
Issued Date
May 31, 2007
Expiration Date
May 31, 2008
Category
Physician
Type
Temporary Physician & Surgeon
Address
Address
Salt Lake City, UT
Personal information
See more information about Guido Jozef Tricot at radaris.comName
Address
Phone
1580 Evergreen Ave, Salt Lake Cty, UT 84106
Professional information
Dr. Guido Tricot, Iowa City IA - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
University Of Iowa Mdcn Spec Cl
200 Hawkins Dr, Iowa City 52242
(319) 356-8133 (Phone)
200 Hawkins Dr, Iowa City 52242
(319) 356-8133 (Phone)
Procedures:
Bone Marrow Biopsy, HPC Transplantation (Stem Cell Transplant), Plasmapheresis
Conditions:
Acute Leukemia, Anemia, Chronic Myeloid Leukemia (CML), Deep Vein Thrombosis (DVT), Leukocytosis, Lymphoma, Macroglobulinemia (incl. Waldenstrom's ), Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, Neutropenia, Non-Hodgkin's Lymphoma, Pancytopenia, Venous Embolism and Thrombosis
Languages:
English
Hospitals:
University Of Iowa Mdcn Spec Cl
200 Hawkins Dr, Iowa City 52242
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
200 Hawkins Dr, Iowa City 52242
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical School
Catholic University Leuven / Faculty of Medicine
Catholic University Leuven / Faculty of Medicine
Dr. Guido J Tricot - MD (Doctor of Medicine)
Hospitals:
Bone Marrow Transplant HEM
1950 Circle Of Hope Dr, Salt Lake City 84112
2000 Circle Of Hope Dr, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Bone Marrow Transplant HEM
1950 Circle Of Hope Dr, Salt Lake City 84112
2000 Circle Of Hope Dr, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
1950 Circle Of Hope Dr, Salt Lake City 84112
2000 Circle Of Hope Dr, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Bone Marrow Transplant HEM
1950 Circle Of Hope Dr, Salt Lake City 84112
2000 Circle Of Hope Dr, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Multiple Myeloma Prognosis And Treatment
US Patent:
2012018, Jul 19, 2012
Filed:
Nov 10, 2011
Appl. No.:
13/293880
Inventors:
Maurizio Zangari - Salt Lake City UT, US
Fenghuang Zhan - Salt Lake City UT, US
Guido Tricot - Salt Lake City UT, US
Fenghuang Zhan - Salt Lake City UT, US
Guido Tricot - Salt Lake City UT, US
International Classification:
A61K 38/05, G01N 33/566, A61P 35/00, A61K 31/407, A61K 38/07, C12Q 1/68, A61K 31/27
US Classification:
514 193, 435 612, 435 723, 436501, 514483, 514421
Abstract:
Disclosed herein are diagnostic and prognostic methods for determining the overall survival, and therapeutic regimes, for multiple myeloma patients. The methods involve the detection of PTHR1 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring treatment of patients having or suspected of having multiple myeloma. The disclosure also relates to proteasome inhibitors and other activators of PTHR1, for the treatment of multiple myeloma.
Multiple Myeloma Prognosis And Treatment
US Patent:
2013010, May 2, 2013
Filed:
Dec 17, 2012
Appl. No.:
13/717264
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Fenghuang ZHAN - Salt Lake City UT, US
Guido TRICOT - Salt Lake City UT, US
Fenghuang ZHAN - Salt Lake City UT, US
Guido TRICOT - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/68, G01N 33/68
US Classification:
435 611, 435 723, 435 614, 435 612
Abstract:
Disclosed herein are diagnostic and prognostic methods for determining the overall survival, and therapeutic regimes, for multiple myeloma patients. The methods involve the detection of PTHR1 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring treatment of patients having or suspected of having multiple myeloma. The disclosure also relates to proteasome inhibitors and other activators of PTHR1, for the treatment of multiple myeloma.